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Abstract
Background: Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct
mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that may
preclude concomitant administration. Concurrent administration of IPI and VEM previously showed significant
dose-limiting hepatotoxicity in advanced melanoma. This single-arm, open-label, phase II study evaluated a
sequencing strategy with these two agents in previously untreated patients with BRAF-mutated advanced melanoma.
Methods: This study was divided into two parts. During Part 1 (VEM1-IPI), patients received VEM 960 mg twice daily for
6 weeks followed by IPI 10 mg/kg every 3 weeks for 4 doses (induction), then every 12 weeks (maintenance)
beginning at week 24 until disease progression or unacceptable toxicity. During Part 2 (VEM2), patients who
progressed after IPI received VEM at their previously tolerated dose. The primary objective was to estimate
the incidence of grade 3/4 drug-related skin adverse events (AEs) during VEM1-IPI.
Results: All patients who were initially treated with VEM (n = 46) received IPI induction therapy; 8 received IPI
maintenance and 19 were treated during VEM2. During VEM1-IPI, the incidence of grade 3/4 drug-related AEs
associated with the skin, GI tract, and hepatobiliary system was 32.6 %, 21.7 %, and 4.3 %, respectively. There
were no drug-related deaths. At a median follow-up of 15.3 months, median overall survival was 18.5 months.
Median progression-free survival was 4.5 months.
Conclusions: VEM (960 mg twice daily for 6 weeks) followed by IPI 10 mg/kg has a manageable safety
profile. The benefits/risks of BRAF inhibitors followed by immunotherapy should be evaluated further in light
of continuing developments in treatment options for metastatic melanoma.
Trial registration: ClinicalTrials.gov identifier: NCT01673854 (CA184-240) Registered 24 August 2012
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Background
The treatment landscape for metastatic melanoma has
shifted dramatically in the past five years with the intro-
duction of immune checkpoint inhibitors and targeted
agents. In 2011, the anti-CTLA-4 antibody YERVOY®
(ipilimumab, IPI; Bristol-Myers Squibb, New York, NY,
USA) and BRAF inhibitor Zelboraf® (vemurafenib, VEM;
Genentech, San Francisco, CA, USA) were approved for
the treatment of metastatic melanoma, marking the first
immune checkpoint inhibitor and the first targeted
agent, respectively, to be approved for this indication.
The dynamics and durability of response observed
with IPI and VEM differ markedly. IPI has demonstrated
a durable survival benefit in ~20 % of patients, ~10 years
from the initial treatment in a proportion of patients;
however, IPI-induced tumor responses often require
time to reach their full potential [1–5]. VEM can induce
rapid and substantial responses in approximately 50 % of
patients with advanced, BRAF-mutated melanoma [6, 7],
but in most cases responses are not durable, as tumors
develop resistance to BRAF inhibition due to activation
of alternate signaling pathways [8, 9]. Patients may ex-
perience rapid disease progression once tumors bypass
BRAF inhibition, often not allowing time for other
therapeutic options to be considered.
Several lines of evidence provide a rationale for com-
bining an immune checkpoint inhibitor with a targeted
agent to optimize patient outcomes (rapid response with
VEM, and durability of response with IPI), while minimiz-
ing toxicity [10]. Tumor cell death mediated by inhibition
of the MAPK pathway may lead to increased antigen pres-
entation or cross-presentation to tumor-specific T cells
[11]. Inhibition of the MAPK pathway has been shown to
increase the expression of melanocyte differentiation
antigens in melanoma cell lines and fresh tumor digests,
conferring enhanced antigen-specific recognition by T
lymphocytes [12]. In co-cultures of melanoma cell lines
and human monocyte-derived dendritic cells, inhibition
of BRAF and MEK restores compromised dendritic cell
function [13].
Concurrent administration of VEM and IPI was evalu-
ated in a phase I study of patients with BRAF-mutated
metastatic melanoma [14]. Patients in the first cohort
(n = 6) received 960 mg VEM twice daily for 4 weeks,
before starting concurrent IPI 3 mg/kg given every
3 weeks for four infusions; in the second cohort (n = 6),
the dose of VEM was reduced to 720 mg twice daily. Four
of six patients in the first cohort experienced grade 3 ele-
vations in aminotransferase levels after the first infusion of
VEM plus IPI. Among the first four patients treated in the
second cohort, two patients experienced grade 3 eleva-
tions in aminotransferase levels after starting IPI. Given
the hepatotoxicity observed with VEM plus IPI, the
remaining two patients in the second cohort received
VEM alone and the study was closed to further patient ac-
crual. All hepatic adverse events (AEs) were asymptomatic
and reversible with discontinuation of study therapy or
administration of glucocorticoids. Two of six patients
in the first cohort experienced grade 3 rash with VEM
plus IPI.
The current study was designed to evaluate a sequen-
cing strategy (VEM followed by IPI), in order to avoid
the toxicities observed with concurrent administration.
The rationale for this treatment sequence was that it
could potentially delay or prevent the emergence of
BRAF inhibitor resistance by initiating IPI before disease
progression, and to optimize a potential immune-
synergy by initiating IPI soon after BRAF-inhibitor in-
duced T-cell infiltration.
This report focuses on patients who were treated with
VEM followed by IPI during Part 1 of the study (VEM1-
IPI). Data collected during Part 2 (subsequent VEM re-
treatment, VEM2) are summarized in brief. Grade 3/4
skin AEs were the most frequent severe common toxic-
ities shared by the two agents and the incidence of these
events was therefore chosen as the primary endpoint.
Grade 3/4 gastrointestinal and hepatobiliary AEs were
evaluated as secondary endpoints.
Methods
Patients
Eligible patients had histologically confirmed unresect-
able stage III or IV malignant melanoma that harbored a
BRAF V600 mutant. Patients had to be at least 18 years
old with measurable disease and an Eastern Cooperative
Oncology Group (ECOG) performance status of 0 or 1.
Prior systemic treatment for melanoma was not permit-
ted. Patients with primary ocular melanoma, active auto-
immune diseases, or symptomatic brain metastases
requiring corticosteroid treatment were ineligible.
All patients provided written informed consent. The
protocol was approved by the institutional review boards
or ethics committees of the participating sites. The study
was conducted in accordance with declaration of
Helsinki with good clinical practice as defined by the
International Conference on Harmonization.
Study design and treatment
This phase II, single-arm, open-label study (CA184-240,
ClinicalTrials.gov identifier: NCT01673854) was carried
out in two parts (Fig. 1a). During Part 1 (VEM1-IPI),
patients received VEM 960 mg orally twice daily for
6 weeks. After a washout period of 3 to 10 days, patients
were initiated on IPI induction at 10 mg/kg every
3 weeks for 4 doses. At week 24, patients received IPI
maintenance at the dose of 10 mg/kg every 12 weeks
until disease progression by modified World Health
Organization (mWHO) criteria or unacceptable toxicity
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• IPI induction (n = 46)
• IPI maintenance (n = 8)
Patients treated during VEM2
(n = 19)
Patients not treated during VEM1
(n = 24)
• Study criteria not met (n = 22)
• Death (n = 1)
• Withdrew consent (n = 1) Discontinuation during IPI treatment
(n = 27)
• IPI induction (n = 19)
o Disease progression (n = 7)
o Study drug toxicity (n = 4)
o AE unrelated to study drug (n = 1)
o Death (n = 1)
o Other (n = 1)
o Not reported (n = 5)
• IPI maintenance (n = 8)
o Administrative reason by sponsor (n = 2)
o Study drug toxicity (n = 2)
o Maximum clinical benefit (n = 1)
o Other (n = 1)
o Not reported (n = 2)
Discontinuation during VEM2
(n = 19)
• Disease progression (n = 12)
• Study drug toxicity (n = 5)
• AE unrelated to study drug (n = 1)
• Death (n = 1)
b
Fig. 1 This study was divided into two parts: VEM1-IPI and VEM2. During VEM1-IPI, patients received VEM 960 mg twice daily for 6 weeks followed by
IPI 10 mg/kg induction and maintenance therapy. During VEM2, patients who progressed after IPI received VEM at their previously tolerated dose (a).
Among 70 patients who enrolled in this study, 46 were treated during VEM1 and continued to IPI induction. Eight patients received IPI maintenance
therapy. Nineteen patients were treated during VEM2. Reasons for discontinuation of study drug are provided (b). AE = adverse event; BID = twice daily;
IPI = ipilimumab; PO = by mouth; PD = progressive disease; Q3W= every 3 weeks; Q12W= every 12 weeks; VEM = vemurafenib
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for a maximum treatment period of 3 years from the
first dose. A higher than approved dose of IPI for ad-
vanced melanoma was selected for this study based on
clinical data showing a greater mean rate of increase in
absolute lymphocyte count and improved efficacy mea-
sures (e.g., BOR) with IPI 10 versus 3 mg/kg [15].
During Part 2 (VEM2), patients without progression
or unacceptable toxicity to VEM during Part 1 (VEM1-
IPI) and who had discontinued IPI were re-treated with
VEM at their previously tolerated dose. A minimum of
1-month washout period between IPI and treatment in
VEM2 was required for patients who stopped IPI
because of toxicity or reasons other than progression.
Patients who proceeded to VEM2 after progression on
IPI maintenance did not have any minimum washout
requirement before re-initiating VEM. Treatment was
continued until disease progression by WHO criteria or
unacceptable toxicity. Tumor response was assessed by
mWHO criteria after completion of VEM1-IPI induction
and then every 12 weeks.
Study objectives
The primary objective was to estimate the incidence of
grade 3/4 drug-related skin AEs during VEM1-IPI. Sec-
ondary objectives were to estimate the rates of grade 3/4
drug-related gastrointestinal (GI) and hepatobiliary AEs
during VEM1-IPI. For both the primary and secondary
objectives, analyses included events that occurred from
the first dose of VEM1 to the last dose of IPI plus
90 days or to the first dose of VEM2, whichever oc-
curred first. Worst grade drug-related skin, GI, and
hepatobiliary AEs were taken into account.
Exploratory objectives included progression-free sur-
vival (PFS), best overall response (BOR), objective re-
sponse rate (ORR), duration of response (DOR),
duration of stable disease (DOSD), and safety during
VEM1-IPI. PFS was defined as the time between the first
dose date of VEM1 and the date of progressive disease
by mWHO criteria or death, whichever occurred first.
BOR analysis was defined over the VEM1-IPI period as a
whole and compared the on-study tumor burden to the
study baseline tumor assessment. ORR was defined as
the number of patients who achieved a BOR of complete
response (CR) or partial response (PR) divided by the
total number of IPI-treated patients. DOR was assessed
in patients who achieved a BOR of CR or PR, and was
defined as the time between the date of confirmed re-
sponse and the date of progressive disease or death,
whichever occurred first. DOSD was defined as the time
between the date of the first evaluable tumor assessment
with at least SD and the date of progressive disease or
death, whichever occurred first. Exploratory safety end-
points included AEs, serious adverse events (SAEs),
drug-related AEs, and AEs leading to discontinuation.
All AEs were coded using Medical Dictionary for Regu-
latory Activities (MedDRA) system organ classes and
preferred terms, and were graded using the National
Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE v3.0).
Although this study was primarily focused on out-
comes during VEM1-IPI, additional data during subse-
quent VEM re-treatment (VEM2) was also collected. All
safety analyses performed during VEM1-IPI were also
performed during VEM2, and included events from the
first dose date of VEM2 to the last dose of VEM2 plus
14 days. ORR during VEM2 was also evaluated.
All treated patients were followed every 12 weeks for
survival.
Statistical analyses
The sample size for this study was not based on power
calculation. It was estimated that approximately 45 eli-
gible patients would be treated during VEM1. Allowing
for a 10 % drop-out prior to IPI treatment, the number
of patients with IPI was expected to be approximately
40. Assuming that the incidence of high-grade skin AEs
was approximately 10 %, a sample size of 40 treated pa-
tients would provide two-sided exact 95 % confidence
intervals (CIs) of 2.8 % to 23.7 %. Time-to-event end-
points (PFS, DOR, DOSD, and OS) were estimated
using the Kaplan-Meier (KM) method. The estimate
of median and two-sided 95 % CIs was calculated by
the Brookmeyer and Crowley method. KM estimates
of PFS rates and associated two-sided log-log transform-
ation 95 % CIs were calculated at multiple time points, in-
cluding 6 months and 1 year. For ORR, exact two-sided
95 % CIs were computed using the Clopper and Pearson
method. For primary and secondary safety endpoints,




Seventy patients were enrolled between October 2012
and July 2014, and 46 were treated during VEM1-IPI
(Fig. 1b). Patient demographic and baseline clinical char-
acteristics during VEM1-IPI are summarized in Table 1.
The mean age of patients was 55.0 years, and 80.4 %
were male. Most patients (76.1 %) had an ECOG per-
formance status of 0. At study entry, most patients had
stage IV disease (82.6 %), M1c (52.2 %), and at least 5
disease sites involved (54.3 %).
Drug exposure
All 46 patients treated with VEM during VEM1 contin-
ued to IPI induction (Fig. 1b). The median number of
doses administered during IPI induction was 4; 24 pa-
tients (52.2 %) received all 4 doses, 8 (17.4 %) received 3
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doses, 8 (17.4 %) received 2 doses, and 6 (13.0 %)
received 1 dose. Eight patients (17.4 %) received IPI
maintenance therapy. The median number of doses ad-
ministered during IPI maintenance was 3; 1 patient each
received 5, 6, or 7 doses; 3 patients received 3 doses and
2 patients received 1 dose. Ten patients (21.7 %) re-
quired at least one IPI dose delay, and 6 (13.0 %) needed
at least one IPI infusion interruption. At the time of this
analysis, all 46 patients had discontinued study treat-
ment: 27 during IPI treatment and 19 during VEM2
treatment (Fig. 1b). Reasons for discontinuation of study
drugs are provided in Fig. 1b.
Safety
During VEM1-IPI, 15 of 46 patients (32.6 %) experi-
enced 1 or more grade 3/4 drug-related skin AEs (e.g.,
rash, erythema, pruritus) (Table 2). Grade 3/4 drug-
related GI AEs occurred in 10 of 46 patients (21.7 %);
diarrhea was the most common (n = 5, 10.9 %). Only 2
of 46 patients (4.3 %) experienced grade 3/4 drug-related
hepatobiliary toxicity: hepatitis (n = 1, 2.2 %) and hyper-
bilirubinemia (n = 1, 2.2 %).
Overall during VEM1-IPI, 43 of 46 (93.5 %) patients
reported a drug-related AE of any grade (Table 3). All 43
patients had 1 or more drug-related AEs that were
consistent with an immune phenomenon. Grade 3/4
drug-related AEs were reported in 30 patients (65.2 %).
Drug-related serious adverse events (SAEs) of any grade
were noted in 18 patients (39.1 %). The only grade 3/4
drug-related SAE observed in 3 or more patients was
squamous cell carcinoma (n = 3, grade 3 events).
Drug-related AEs of any grade leading to discontinu-
ation of treatment during VEM1-IPI were most frequently
seen as GI disorders (21.7 %), including colitis and diar-
rhea (6.5 % each), nausea and vomiting (4.3 % each); all
other system-organ events leading to discontinuation were
each reported in only 1 patient.
During VEM2, drug-related AEs of any grade were
observed in 10 of 19 patients (52.6 %). Five patients
(26.3 %) experienced a grade 3 drug-related AE during
VEM2.
Twenty-four patients (52.2 %) died during this study
due to disease (n = 22) or other/unknown factors (n = 2).
There were no drug-related deaths.
Efficacy
During VEM1-IPI, the BOR rate was 32.6 % (Table 4).
The median duration of response was 23.1 months
(95 % CI: 5.03–not evaluable), and the median duration
of stable disease was 5.2 months (95 % CI: 3.98–14.75)
(Table 4, Fig. 2). The BOR rate during VEM2 was 36.8 %.
The median PFS during VEM1-IPI was 4.5 months (95 %
Table 1 Patient demographic and baseline clinical characteristics
Characteristic VEM1-IPI (n = 46)
Age, years
Mean (SD) 55.0 (14.20)
Gender, n (%)
Male 37 (80.4)
ECOG performance status, n (%)
0 35 (76.1)
1 11 (23.9)
Disease stage at study entry, n (%)
III 8 (17.4)
IV 38 (82.6)










≥ 5 25 (54.3)
ECOG Eastern Cooperative Oncology Group, IPI ipilimumab, SD standard
deviation, VEM vemurafenib
Table 2 Drug-related grade 3/4 skin, gastrointestinal, and
hepatobiliary AEs during VEM1-IPI by investigator-reported
preferred term




Exfoliative rash 2 (4.3)
Pruritus 2 (4.3)
Rash generalized 2 (4.3)
Rash maculo-papular 1 (2.2)




Abdominal pain 1 (2.2)
Autoimmune colitis 1 (2.2)
Vomiting 1 (2.2)
Hepatobiliary disorders 2 (4.3)
Hepatitis 1 (2.2)
Hyperbilirubinemia 1 (2.2)
AE adverse event, IPI ipilimumab, VEM vemurafenib
aPatients may have experienced more than 1 event
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CI: 4.17–6.57) (Fig. 3a). At a median follow-up of
15.3 months, the median OS was 18.5 months (95 % CI:
11.96–not evaluable) (Fig. 3b).
Discussion
This phase II, single-arm, open-label study showed that
VEM (960 mg twice daily for 6 weeks) followed by IPI
10 mg/kg can be administered safely in patients with
previously untreated BRAF-mutated metastatic melan-
oma. Although 65.2 % of the patients experienced a
grade 3/4 drug-related AE, no drug-related deaths oc-
curred. During VEM1-IPI, grade 3/4 drug-related skin
AEs were observed in 32.6 % of patients, which is higher
than that reported with IPI 10 mg/kg alone (grade 3/4
immune-related skin AEs: 4.2 % in the phase II study
CA184-022 and 3.2 % in the phase II study CA184-008)
or VEM monotherapy (grade 3 rash: 8 % in the phase III
study BRIM-3) [6, 15, 16]. Interestingly, the incidence of
grade 3 squamous cell carcinoma in this study (6.5 %
based on NCI CTCAE v3.0) was lower than that
reported with VEM monotherapy (12 % based on NCI
CTCAE v4.0), which is possibly due to the shorter
duration of VEM therapy (6 weeks) in our study [6].
Alternatively, this may suggest a role for the immune re-
sponse in the development of secondary squamous cell
carcinomas in light of the possible etiologies of their
development via HRAS mutations in keratinocytes [17].
The incidence of drug-related grade 3/4 diarrhea
(10.9 %) and colitis (4.3 %) reported here is similar to
that observed with IPI 10 mg/kg alone (CA184-022:
14.1 % and 2.8 %, respectively) [18]. In contrast to the
high hepatotoxicity noted with concurrent administra-
tion of VEM and IPI (4 of 6 patients [66.7 %] treated
with VEM 960 mg/kg in cohort 1) [14], only 2 of 46 pa-
tients (4.3 %) experienced grade 3/4 hepatotoxicity with
this VEM/IPI sequencing regimen (Table 2), suggesting
that sequential administration of VEM and IPI results in
a better toxicity profile than concurrent administration.
The BOR observed during VEM1-IPI was 32.6 %,
which is higher than that reported with IPI 10 mg/kg
alone (11.1 % in CA184-022 and 5.8 % in CA184-008)
[15, 16], and lower than that reported with VEM mono-
therapy (ORR: 57 % in BRIM-3) [19]. The response ob-
served and reported in this study was captured at the
end of completion of 4 doses of induction therapy with
IPI and therefore does not necessarily reflect best
response to VEM monotherapy at the end of the initial
6-week treatment. Some of the patients with rapidly pro-
gressive disease could potentially have had an increase
in their tumor burden while receiving IPI prior to the
first response evaluation of the study. During VEM1-IPI,
the median duration of response was 23.1 months, and
the median duration of stable disease was 5.2 months.
The median duration of response was 19.3 months in
the phase III study CA184-024, which evaluated IPI
Table 3 Drug-related AEs during VEM1-IPI
Event, n (%)a VEM1-IPI (n = 46)
Any Grade Grade 3 Grade 4
Any drug-related AE 43 (93.5) 27 (58.7) 3 (6.5)
AEs occurring in≥ 3 patientsb
Rash 28 (60.9) 9 (19.6) 0 (0)
Diarrhea 17 (37.0) 5 (10.9) 0 (0)
AST increased 9 (19.6) 3 (6.5) 1 (2.2)
ALT increased 8 (17.4) 4 (8.7) 0 (0)
Squamous cell carcinomac 3 (6.5) 3 (6.5) 0 (0)
Any drug-related serious AEs 18 (39.1) 15 (32.6) 2 (4.3)
AEs leading to discontinuation of treatment 16 (34.8) 9 (19.6) 1 (2.2)
AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, IPI ipilimumab, VEM vemurafenib
aPatients may have experienced more than 1 event
bOnly toxicities that reached Grade 3/4 in severity in ≥ 3 patients are presented
cSquamous cell carcinoma was classified as a serious adverse event (SAE) and was the only SAE that was observed in 3 or more patients (n = 3, grade 3 events)
Table 4 Efficacy results during VEM1-IPI
Result
Best overall response, n (%)
Complete response 2 (4.3)
Partial response 13 (28.3)
Stable disease 5 (10.9)
Progressive disease 11 (23.9)
Unknowna 15 (32.6)
Best overall response rate, % (95 % CI) 32.6 (19.5–48.0)
Median duration of response, mo (95 % CI) 23.1 (5.03–NE)
Median duration of stable disease, mo (95 % CI) 5.2 (3.98–14.75)
CI confidence interval, IPI ipilimumab, mo month, NE not evaluable,
VEM vemurafenib
aResponse could not be determined due to missing assessment, image
quality, etc
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10 mg/kg in combination with dacarbazine in patients
with unknown BRAF mutation status [4], and was
6.7 months with VEM in the BRIM-2 study [7]. The
BOR was 36.8 % during VEM2, showing ongoing sensi-
tivity to BRAF inhibition.
The landscape of therapeutic options for advanced
melanoma continues to evolve rapidly. Combinations of
BRAF plus MEK inhibitors (e.g., dabrafenib plus trameti-
nib, as well as vemurafenib plus cobimetinib) have
shown an overall response rate of 66–70 % in patients
with BRAF-mutated advanced melanoma [20–22] and
are now approved for this indication by the US FDA.
Several studies of PD-1 inhibition alone or in combin-
ation with IPI have included treatment-naïve patients
with BRAF-mutated advanced melanoma who could
have been eligible for our study. The ORR observed with
PD-1 inhibition alone (i.e., nivolumab [NIVO] or pem-
brolizumab) is in the range of 33–37 %, while the com-
bination of NIVO plus IPI elicited an ORR of 52–67 %
[23–26]. NIVO and pembrolizumab as monotherapy and
NIVO in combination with IPI are now approved
treatments for advanced melanoma. It is important to
keep the above data in mind to contextualize this study
in current clinical practice.
Although a number of very effective agents are now
available for advanced melanoma, the best dosing sched-
ules, combinations or sequencing are still not known
and remain the focus of active investigation. As an
example, a phase II, randomized study (CheckMate 064)
showed consistent improvement in efficacy outcomes
with NIVO followed by IPI versus IPI followed by NIVO
(e.g., confirmed ORR at week 25: 41.2 % versus 20.0 %,
respectively) [27]. The pattern of AEs reported in Check-
Mate 064 was similar to that previously reported with ei-
ther agent, alone or in combination, whereas the
frequency of AEs was consistent with previous reports
for NIVO plus IPI [23, 24].
The sequencing strategy of targeted therapy followed
by immune-modulation, demonstrated in this study with
VEM followed by IPI, serves as one of the links in our
efforts to understand how best to use these agents. Add-
itional understanding of the immune-modulatory effects
Patients at Risk
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Fig. 2 Kaplan-Meier curves for DOR (a) and DOSD (b) during VEM1-IPI. The median DOR was 23.1 months (95 % CI: 5.03–not evaluable), and the
median DOSD was 5.2 months (95 % CI: 3.98–14.75)
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of BRAF as well as MEK inhibition in the tumor micro-
environment is warranted. MEK inhibition may influence
the activity of certain subsets of effector lymphocytes.
BRAF inhibition with VEM may also activate lymphocytes
via the paradoxical activation of MAPK in BRAF wild-type
cells and contribute not only to some of the side effects
observed with the combination of immunotherapy, but
also to improved antitumor activity and clinical outcomes.
This study sets the stage for further investigation of BRAF
plus MEK inhibition followed by PD-1 with or without
CTLA-4 inhibition for select groups of patients who have
high tumor burden or rapidly progressive symptomatic
disease, which will be borne out in the phase III ECOG
study (NCT02224781) currently underway to evaluate
dabrafenib plus trametinib followed by IPI plus NIVO at
progression compared with IPI plus NIVO followed by
dabrafenib plus trametinib at progression in patients with
BRAF V600-mutant advanced melanoma.
Regardless of recent developments exploring multiple
sequential combinations, further investigation of the
potential of BRAF inhibition combined with immune
checkpoint inhibition, especially the PD-1 pathway, may
be worthwhile. Our study showed that the sequential
combination of VEM and IPI had manageable safety and
that tumors remain sensitive to BRAF inhibition after
progressing on immunotherapy with IPI.
Conclusions
We show that VEM (960 mg twice daily for 6 weeks)
followed by IPI 10 mg/kg has a manageable safety profile.
Although the combination of BRAF plus MEK inhibition








1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26






























10 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Months
Patients at Risk














Fig. 3 Kaplan-Meier curves for PFS during VEM1-IPI (a) and OS (b). The median PFS was 4.5 months (95 % CI: 4.17–6.57). At a median follow-up of
15.3 months, the median OS was 18.5 months (95 % CI: 11.96–not evaluable)
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commonly used today than VEM or IPI monotherapy to
treat advanced melanoma, this study shows that IPI has
efficacy after treatment with VEM in patients with BRAF-
mutated melanoma and that tumors remain sensitive to
VEM re-treatment after progressing on IPI. In addition,
because VEM and IPI are the major drivers of the AE pro-
file associated with combination regimens (e.g., AE profile
of NIVO plus IPI is primarily driven by IPI), evaluation of
each agent alone may be informative regarding the safety
profile of combination therapy when used in a sequential
regimen. The benefits/risks of BRAF inhibitors followed
by immunotherapy should be evaluated further in
light of continuing developments in treatment options
for metastatic melanoma.
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